User:Mr. Ibrahem/Cidofovir

Mr. Ibrahem/Cidofovir
Clinical data
Trade names	Vistide
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US FDA: Cidofovir;
Pregnancy; category	AU: D; ;
Routes of; administration	IV
Drug class	Antiviral
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	Complete
Protein binding	<6%
Elimination half-life	2.6 hours (active metabolites: 15-65 hours)
Excretion	Kidney The above pharmacokinetics are with probenecid.
Identifiers
	IUPAC name ({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid;
Chemical and physical data
Formula	C8H14N3O6P
Molar mass	279.189 g·mol−1
3D model (JSmol)	Interactive image;
Specific rotation	-97.3
Melting point	260 °C (500 °F)
	SMILES O=C1/N=C(\C=C/N1C[C@H](OCP(=O)(O)O)CO)N;
	InChI InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1 ; Key:VWFCHDSQECPREK-LURJTMIESA-N ;
	(verify)

Cidofovir, sold under the brand name Vistide, is an antiviral used to treat cytomegalovirus (CMV) retinitis in people with HIV/AIDS.^[1] Is also used for herpes simplex virus that is resistant to acyclovir, monkeypox, and certain complications of smallpox vaccination.^[1] It is generally given by injection into a vein.^[1]

Common side effects include kidney problems, nausea, fever, low white blood cells, headache, rash, hair loss, diarrhea, and heart burn.^[1] Other side effects may include pancreatitis, male infertility, and hearing loss.^[3] It is given with intravenous fluids and probenecid to decrease the risk of kidney problems.^[3] There are concerns that use in pregnancy may harm the baby.^[1] It works by blocking the DNA polymerase of the virus.^[3]

Cidofovir was approved for medical use in the United States 1996.^[4] It is available as a generic medication.^[3] In the United States 375 mg costs about 215 USD as of 2021.^[5]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h "Cidofovir Monograph for Professionals". Drugs.com. Archived from the original on 8 February 2018. Retrieved 5 January 2022.
^ Cundy, Kenneth C. "Clinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and Adefovir." Clinical Pharmacokinetics 36.2 (1999): 127-43.
^ ^a ^b ^c ^d ^e BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 676. ISBN 978-0857114105.
^ Long, Sarah S.; Pickering, Larry K.; Prober, Charles G. (2012). Principles and Practice of Pediatric Infectious Disease. Elsevier Health Sciences. p. 1502. ISBN 978-1437727029. Archived from the original on 2019-12-29. Retrieved 2021-07-27.
^ "Cidofovir Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 19 September 2016. Retrieved 5 January 2022.

[AHFS2022-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h "Cidofovir Monograph for Professionals". Drugs.com. Archived from the original on 8 February 2018. Retrieved 5 January 2022.

[2] Cundy, Kenneth C. "Clinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and Adefovir." Clinical Pharmacokinetics 36.2 (1999): 127-43.

[BNF81-3] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 676. ISBN 978-0857114105.

[4] Long, Sarah S.; Pickering, Larry K.; Prober, Charles G. (2012). Principles and Practice of Pediatric Infectious Disease. Elsevier Health Sciences. p. 1502. ISBN 978-1437727029. Archived from the original on 2019-12-29. Retrieved 2021-07-27.

[5] "Cidofovir Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 19 September 2016. Retrieved 5 January 2022.

[1]

[2]

[3]

[4]

[5]